An Update on Eight “New” Antibiotics against Multidrug-Resistant Gram-Negative Bacteria
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An Update on Eight “New” Antibiotics against Multidrug-Resistant Gram-Negative Bacteria
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 10, Issue 5, Pages 1068
Publisher
MDPI AG
Online
2021-03-05
DOI
10.3390/jcm10051068
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Comparison of Treatment Outcomes Between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients With Imipenem-Nonsusceptible Bacterial Infections
- (2020) Keith S. Kaye et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
- (2020) Renee Ackley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ARGONAUT II - In vitro activity of plazomicin against carbapenemase-producing Klebsiella pneumoniae
- (2020) Michael R. Jacobs et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016
- (2020) Shu-Chen Kuo et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Early Experience with Eravacycline for Complicated Infections
- (2020) S Alosaimy et al. Open Forum Infectious Diseases
- Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections
- (2020) Sara Alosaimy et al. Open Forum Infectious Diseases
- Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016–2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides
- (2020) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
- (2020) Matteo Bassetti et al. Open Forum Infectious Diseases
- Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Co-Resistance, and Region
- (2020) Brian D. Johnston et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
- (2020) Ivan Titov et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort
- (2020) Juan José Castón et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany
- (2020) Michael Kresken et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18
- (2020) Helio S Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cefiderocol Antimicrobial Susceptibility Testing Considerations: The Achilles Heel of the Trojan Horse?
- (2020) Patricia J. Simner et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016–2018
- (2020) Helio S. Sader et al. Microbial Drug Resistance
- In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems
- (2020) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- (2020) Richard G Wunderink et al. LANCET INFECTIOUS DISEASES
- Once-Daily Plazomicin for Complicated Urinary Tract Infections
- (2019) Florian M.E. Wagenlehner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
- (2019) James A. McKinnell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections
- (2019) Khalid Eljaaly et al. DRUGS
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
- (2019) George G. Zhanel et al. DRUGS
- Eravacycline: The Tetracyclines Strike Back
- (2019) Maria Heaney et al. ANNALS OF PHARMACOTHERAPY
- Comparison of ceftazidime-avibactam and Ceftolozane-Tazobactam in vitro activities when tested against gram-negative Bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018)
- (2019) Helio S. Sader et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae
- (2019) Matthew C. Canver et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa
- (2019) Jason M Pogue et al. CLINICAL INFECTIOUS DISEASES
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- (2019) Johann Motsch et al. CLINICAL INFECTIOUS DISEASES
- 42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance study
- (2019) George G Zhanel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
- (2019) Marin H Kollef et al. LANCET INFECTIOUS DISEASES
- In Vitro Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Clinical Isolates of Meropenem-Non-Susceptible Pseudomonas aeruginosa: A Two-Center Study
- (2019) Hasan Cenk Mirza et al. Journal of Global Antimicrobial Resistance
- Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals During 2016-2018
- (2019) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections
- (2019) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Plazomicin-associated nephrotoxicity
- (2019) Hung-Jen Tang et al. CLINICAL INFECTIOUS DISEASES
- Activity of temocillin against KPC-producing Enterobacteriaceae clinical isolates
- (2019) Athanasios Tsakris et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis
- (2018) Lynn E. Connolly et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015
- (2018) George G. Zhanel et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Activity of temocillin against CTX-M-producing Escherichia coli and Klebsiella pneumoniae from Germany
- (2018) Michael Kresken et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection
- (2018) Keith S. Kaye et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
- (2018) Gregory G Stone et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- (2018) Evelina Tacconelli et al. LANCET INFECTIOUS DISEASES
- The global distribution and spread of the mobilized colistin resistance gene mcr-1
- (2018) Ruobing Wang et al. Nature Communications
- Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes
- (2018) Georgina Cox et al. ACS Infectious Diseases
- Past and Present Perspectives on β-Lactamases
- (2018) Karen Bush ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis
- (2018) Han Zhong et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms
- (2018) Mariana Castanheira et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
- (2018) Michael R. Jacobs et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections
- (2018) Joseph S Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Plazomicin: A Next-Generation Aminoglycoside
- (2018) Kristy M. Shaeer et al. PHARMACOTHERAPY
- Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
- (2018) Jason C Gallagher et al. Open Forum Infectious Diseases
- The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection
- (2018) Soichi Arakawa et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
- (2017) Xinyu Qin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates
- (2017) Valérie Denervaud-Tendon et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles
- (2017) David M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial
- (2017) Joseph Solomkin et al. JAMA Surgery
- Eravacycline Is Active against Bacterial Isolates Expressing the Polymyxin Resistance Genemcr-1
- (2016) Corey Fyfe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii
- (2016) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study
- (2016) Benjamin Miller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
- (2016) Florian M. Wagenlehner et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
- (2016) David van Duin et al. CLINICAL INFECTIOUS DISEASES
- Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials
- (2016) Myra W. Popejoy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
- (2016) Yehuda Carmeli et al. LANCET INFECTIOUS DISEASES
- Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
- (2015) Joseph Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
- (2015) Florian M Wagenlehner et al. LANCET
- Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections
- (2014) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013
- (2013) C Glasner et al. Eurosurveillance
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
- (2013) L Silvia Munoz-Price et al. LANCET INFECTIOUS DISEASES
- Metallo-β-lactamase structure and function
- (2012) Timothy Palzkill Annals of the New York Academy of Sciences
- OXA-48-like carbapenemases: the phantom menace
- (2012) L. Poirel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae
- (2011) Indran Balakrishnan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of Temocillin against KPC-Producing Klebsiella pneumoniae and Escherichia coli
- (2009) J. M. Adams-Haduch et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
- (2009) Jean-Louis Vincent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Temocillin revived
- (2008) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started